A61K 51/1027
Against receptors, cell-surface antigens or cell-surface determinants
Official title: {against receptors, cell-surface antigens or cell-surface determinants}
A61K51/1027 (Against receptors, cell-surface antigens or cell-surface determinants) appears on 479 US grants and 869 published applications in this corpus.
Search patents in A61K- Granted patents
- 479
- Published applications
- 869
- Assignees
- 387
- Inventors
- 1,571
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 0 | 0 |
| 1995 | 5 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 13 | 0 |
| 1999 | 10 | 0 |
| 2000 | 5 | 0 |
| 2001 | 9 | 1 |
| 2002 | 12 | 11 |
| 2003 | 6 | 17 |
| 2004 | 6 | 18 |
| 2005 | 3 | 18 |
| 2006 | 7 | 22 |
| 2007 | 8 | 28 |
| 2008 | 10 | 15 |
| 2009 | 9 | 29 |
| 2010 | 16 | 34 |
| 2011 | 10 | 39 |
| 2012 | 17 | 30 |
| 2013 | 29 | 35 |
| 2014 | 32 | 55 |
| 2015 | 17 | 47 |
| 2016 | 27 | 46 |
| 2017 | 33 | 39 |
| 2018 | 32 | 36 |
| 2019 | 22 | 39 |
| 2020 | 16 | 38 |
| 2021 | 18 | 34 |
| 2022 | 21 | 40 |
| 2023 | 11 | 46 |
| 2024 | 23 | 68 |
| 2025 | 24 | 40 |
| 2026 | 14 | 44 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases8 Sep 2026US 12,728,176 B2Actinium Pharmaceuticals, Inc.
- DR5 radioimmunotherapy in the treatment of solid cancers1 Sep 2026US 12,721,913 B2Actinium Pharmaceuticals, Inc.
- Radiolabeled anti-LAG3 antibodies for immuno-PET imaging1 Sep 2026US 12,721,914 B2Regeneron Pharmaceuticals, Inc.
- HER3 radioimmunotherapy for the treatment of solid cancers1 Sep 2026US 12,721,915 B2Actinium Pharmaceuticals, Inc.
- Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)25 Aug 2026US 12,714,745 B2Baylor Research Institute
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Anti-pd-l1 nanobody, preparation method therefor and use thereof1 Oct 2026US 2026/0297195 A1Kanglitai Biomedical (Qingdao) Co., Ltd.
- Radiolabeled activated ester and precursor thereof24 Sep 2026US 2026/0284238 A1Institute of Science Tokyo
- Novel anti-gprc5d antibody24 Sep 2026US 2026/0285972 A1Chimagen Biosciences, Ltd.
- Mutant fab fragment for obtaining site-specific mono-or bifunctionalised conjugates10 Sep 2026US 2026/0265367 A1
Most cited
By later US patents
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma287US 5,776,456 AIDEC Pharmaceuticals Corporation · 1998
- Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody199US 6,455,043 B1IDEC Pharmaceuticals Corporation · 2002
- Internalizing anti-CD74 antibodies and methods of use171US 7,312,318 B2Immunomedics, Inc. · 2007
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma152US 5,843,439 A1998
- Anti-CD20 antibodies147US 7,422,739 B2Biogen Idec Inc. · 2008